agent

(redirected from cytotoxic agent)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial.
Related to cytotoxic agent: cytotoxic drugs, Cytotoxins

agent

a person representing a business concern, esp a travelling salesman

Agent

 

in Soviet civil law, a party in a contract of agency. The agent’s duties include the performance of specified legal acts, for example, contracts of sale and management of property, in the name of and on the account of a principal party. The agent may be a legally competent (sui juris) citizen or a legal person (if this is allowed by the latter’s charter or statute). The actions performed by the agent directly generate, change, or extinguish rights and obligations of the principal.

The agent is bound to perform the agency in exact conformity with the principal’s instructions, carry out the agency personally, although in instances provided for by law the responsibilities may be transferred to another person (art. 68 of the RSFSR Civil Code), inform the principal upon demand of progress in performing the agency, submit a report on performance of the agency, and transfer to the principal any property obtained in connection with performance of the agency.

agent

One who is empowered to enter into binding transactions on behalf of another (usually called the principal).

agent

(networking)
In the client-server model, the part of the system that performs information preparation and exchange on behalf of a client or server. Especially in the phrase "intelligent agent" it implies some kind of automatic process which can communicate with other agents to perform some collective task on behalf of one or more humans.

agent

A software routine that waits in the background and performs an action when a specified event occurs. For example, agents could transmit a summary file on the first day of the month or monitor incoming data and alert the user when a certain transaction has arrived. Agents are also called "intelligent agents," "personal agents" and "bots." See mobile agent, bot and workflow.
References in periodicals archive ?
When cytotoxic agents are ordered for the treatment of cancer, the protocols are typically readily available, and the drugs are ordered, dispensed, and administered by specially trained health care professionals.
With over a decade of experience and knowledge in ADC innovation, Seattle Genetics has developed proprietary technology employing synthetic cytotoxic agents, such as monomethyl auristatin E (MMAE), and stable linker systems that attach these cytotoxic agents to the antibody.
A total of 27 patients elected to receive a cytotoxic agent.
Under the collaboration, the two companies will produce the ADCs using PolyTherics' proprietary TheraPEG[TM] linker technology to site-specifically conjugate Spirogen's potent pyrrolobenzodiazepines ("PBDs") cytotoxic agents - known as warheads - to antibodies and antibody fragments.
This resulted in increased anti-tumor efficacy at a given dose of a cytotoxic agent.
Vintafolide is an investigational, proprietary, injectable SMDC consisting of folate (vitamin B9) linked to a potent vinca alkaloid cytotoxic agent, desacetylvinblastine hydrazide (DAVLBH).
BIND-014 is a targeted polymeric nanoparticle containing the cytotoxic agent docetaxel (Taxotere), which is approved in major cancer indications including breast, prostate and lung.
Kadcyla consists of Roche's trastuzumab antibody with ImmunoGen's DM1 cytotoxic agent attached using one of the company's engineered linkers.
The basic principle of antibody-drug conjugates is to use the antibody moiety for targeting the tumor and for tumor-specific delivery of a cytotoxic agent.
Serina Therapeutics' president and chief executive officer, Dr Randall Moreadith, said, 'The ability to target antibodies that are "pay-loaded" with a potent cytotoxic agent has started to produce the first generation of approved antibody drug conjugates.
Pipeline agents holding the greatest commercial potential include the immunoconjugated monoclonal antibodies Arzerra (ofatumumab; Genmab/GlaxoSmithKline), galiximab (Biogen Idec) and lumiliximab (Biogen Idec), as well as the cytotoxic agent pixantrone (Novartis).
This resulted in increased anti-tumor efficacy at a given dose of the cytotoxic agent, and thus might allow physicians to maximize efficacy of reduced cytotoxic agent doses with resultant decreased toxicity to the normal organs.